Trabectedin, Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent Leiomyosarcoma

NCT03437070 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Sponsor Decision

Conditions

Leiomyosarcoma

Interventions

DRUG: Trabectedin
DRUG: Doxorubicin
DRUG: Olaratumab

Sponsor

University of Miami

Collaborators

[object Object]